EBMT 2022 | A new scoring system for early relapse prediction after autoHSCT in multiple myeloma
Meral Beksac, MD, Ankara University, Ankara, Turkey, comments on the results of a study evaluating a new post-autologous hematopoietic stem cell transplant (autoHSCT) relapse prediction score in patients with low, intermediate, and high-risk multiple myeloma. Prior to this study, parameters associated with early relapse post-transplant included measurable residual disease (MRD), cytogenetics, and failure to achieve complete response (CR) before autoHSCT. In this study, the patients’ International Staging System (ISS) score at diagnosis, response to induction, and their performance status were combined together into a single score dividing patients into five categories. This score was found to be accurate in predicting the relapse rate post-transplant, including in high-risk patients. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
